Aktienanalyse zu Ascendis Pharma A/S (ASND)ASNDAscendis Pharma A/S

Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ascendis Pharma A/S (ASND) is a strong buy at the current price of $247.91, supported by a recent earnings surprise of 321.79% and a forward P/E ratio of 14.60, which indicates potential undervaluation. The positive momentum from the recent inclusion in the Russell Indexes is expected to enhance liquidity and visibility, driving demand for the stock. However, a significant risk is the hedge fund selling, which has increased by 565.41% over the last quarter, indicating potential bearish sentiment among institutional investors.

6 analysts cover ASND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 277.08.